Global Immune Checkpoint Agents Market Research Report 2021
Table of Contents1 Immune Checkpoint Agents Market Overview
1.1 Product Overview and Scope of Immune Checkpoint Agents
1.2 Immune Checkpoint Agents Segment by Type
1.2.1 Global Immune Checkpoint Agents Sales Growth Rate Comparison by Type (2021-2027)
1.2.2 Anti-PD-L1 Drug
1.2.3 Anti-PD-1 Drug
1.2.4 CTLA4
1.3 Immune Checkpoint Agents Segment by Application
1.3.1 Immune Checkpoint Agents Sales Comparison by Application: (2021-2027)
1.3.2 Lung Cancer
1.3.3 Colorectal Cancer
1.3.4 BreastCancer
1.3.5 Prostate Cancer
1.3.6 Melanoma
1.3.7 Blood Cancers
1.4 Global Immune Checkpoint Agents Market Size Estimates and Forecasts
1.4.1 Global Immune Checkpoint Agents Revenue 2016-2027
1.4.2 Global Immune Checkpoint Agents Sales 2016-2027
1.4.3 Immune Checkpoint Agents Market Size by Region: 2016 Versus 2021 Versus 2027
2 Immune Checkpoint Agents Market Competition by Manufacturers
2.1 Global Immune Checkpoint Agents Sales Market Share by Manufacturers (2016-2021)
2.2 Global Immune Checkpoint Agents Revenue Market Share by Manufacturers (2016-2021)
2.3 Global Immune Checkpoint Agents Average Price by Manufacturers (2016-2021)
2.4 Manufacturers Immune Checkpoint Agents Manufacturing Sites, Area Served, Product Type
2.5 Immune Checkpoint Agents Market Competitive Situation and Trends
2.5.1 Immune Checkpoint Agents Market Concentration Rate
2.5.2 The Global Top 5 and Top 10 Largest Immune Checkpoint Agents Players Market Share by Revenue
2.5.3 Global Immune Checkpoint Agents Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.6 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Immune Checkpoint Agents Retrospective Market Scenario by Region
3.1 Global Immune Checkpoint Agents Retrospective Market Scenario in Revenue by Region: 2016-2021
3.2 Global Immune Checkpoint Agents Retrospective Market Scenario in Sales by Region: 2016-2021
3.3 North America Immune Checkpoint Agents Market Facts & Figures by Country
3.3.1 North America Immune Checkpoint Agents Sales by Country
3.3.2 North America Immune Checkpoint Agents Revenue by Country
3.3.3 U.S.
3.3.4 Canada
3.4 Europe Immune Checkpoint Agents Market Facts & Figures by Country
3.4.1 Europe Immune Checkpoint Agents Sales by Country
3.4.2 Europe Immune Checkpoint Agents Revenue by Country
3.4.3 Germany
3.4.4 France
3.4.5 U.K.
3.4.6 Italy
3.4.7 Russia
3.5 Asia Pacific Immune Checkpoint Agents Market Facts & Figures by Region
3.5.1 Asia Pacific Immune Checkpoint Agents Sales by Region
3.5.2 Asia Pacific Immune Checkpoint Agents Revenue by Region
3.5.3 China
3.5.4 Japan
3.5.5 South Korea
3.5.6 India
3.5.7 Australia
3.5.8 Taiwan
3.5.9 Indonesia
3.5.10 Thailand
3.5.11 Malaysia
3.5.12 Philippines
3.5.13 Vietnam
3.6 Latin America Immune Checkpoint Agents Market Facts & Figures by Country
3.6.1 Latin America Immune Checkpoint Agents Sales by Country
3.6.2 Latin America Immune Checkpoint Agents Revenue by Country
3.6.3 Mexico
3.6.4 Brazil
3.6.5 Argentina
3.7 Middle East and Africa Immune Checkpoint Agents Market Facts & Figures by Country
3.7.1 Middle East and Africa Immune Checkpoint Agents Sales by Country
3.7.2 Middle East and Africa Immune Checkpoint Agents Revenue by Country
3.7.3 Turkey
3.7.4 Saudi Arabia
3.7.5 U.A.E
4 Global Immune Checkpoint Agents Historic Market Analysis by Type
4.1 Global Immune Checkpoint Agents Sales Market Share by Type (2016-2021)
4.2 Global Immune Checkpoint Agents Revenue Market Share by Type (2016-2021)
4.3 Global Immune Checkpoint Agents Price by Type (2016-2021)
5 Global Immune Checkpoint Agents Historic Market Analysis by Application
5.1 Global Immune Checkpoint Agents Sales Market Share by Application (2016-2021)
5.2 Global Immune Checkpoint Agents Revenue Market Share by Application (2016-2021)
5.3 Global Immune Checkpoint Agents Price by Application (2016-2021)
6 Key Companies Profiled
6.1 Bristol Myers Squibb
6.1.1 Bristol Myers Squibb Corporation Information
6.1.2 Bristol Myers Squibb Description and Business Overview
6.1.3 Bristol Myers Squibb Immune Checkpoint Agents Sales, Revenue and Gross Margin (2016-2021)
6.1.4 Bristol Myers Squibb Product Portfolio
6.1.5 Bristol Myers Squibb Recent Developments/Updates
6.2 Merck
6.2.1 Merck Corporation Information
6.2.2 Merck Description and Business Overview
6.2.3 Merck Immune Checkpoint Agents Sales, Revenue and Gross Margin (2016-2021)
6.2.4 Merck Product Portfolio
6.2.5 Merck Recent Developments/Updates
6.3 AstraZeneca
6.3.1 AstraZeneca Corporation Information
6.3.2 AstraZeneca Description and Business Overview
6.3.3 AstraZeneca Immune Checkpoint Agents Sales, Revenue and Gross Margin (2016-2021)
6.3.4 AstraZeneca Product Portfolio
6.3.5 AstraZeneca Recent Developments/Updates
6.4 Roche
6.4.1 Roche Corporation Information
6.4.2 Roche Description and Business Overview
6.4.3 Roche Immune Checkpoint Agents Sales, Revenue and Gross Margin (2016-2021)
6.4.4 Roche Product Portfolio
6.4.5 Roche Recent Developments/Updates
7 Immune Checkpoint Agents Manufacturing Cost Analysis
7.1 Immune Checkpoint Agents Key Raw Materials Analysis
7.1.1 Key Raw Materials
7.1.2 Key Suppliers of Raw Materials
7.2 Proportion of Manufacturing Cost Structure
7.3 Manufacturing Process Analysis of Immune Checkpoint Agents
7.4 Immune Checkpoint Agents Industrial Chain Analysis
8 Marketing Channel, Distributors and Customers
8.1 Marketing Channel
8.2 Immune Checkpoint Agents Distributors List
8.3 Immune Checkpoint Agents Customers
9 Immune Checkpoint Agents Market Dynamics
9.1 Immune Checkpoint Agents Industry Trends
9.2 Immune Checkpoint Agents Growth Drivers
9.3 Immune Checkpoint Agents Market Challenges
9.4 Immune Checkpoint Agents Market Restraints
10 Global Market Forecast
10.1 Immune Checkpoint Agents Market Estimates and Projections by Type
10.1.1 Global Forecasted Sales of Immune Checkpoint Agents by Type (2022-2027)
10.1.2 Global Forecasted Revenue of Immune Checkpoint Agents by Type (2022-2027)
10.2 Immune Checkpoint Agents Market Estimates and Projections by Application
10.2.1 Global Forecasted Sales of Immune Checkpoint Agents by Application (2022-2027)
10.2.2 Global Forecasted Revenue of Immune Checkpoint Agents by Application (2022-2027)
10.3 Immune Checkpoint Agents Market Estimates and Projections by Region
10.3.1 Global Forecasted Sales of Immune Checkpoint Agents by Region (2022-2027)
10.3.2 Global Forecasted Revenue of Immune Checkpoint Agents by Region (2022-2027)
11 Research Finding and Conclusion
12 Methodology and Data Source
12.1 Methodology/Research Approach
12.1.1 Research Programs/Design
12.1.2 Market Size Estimation
12.1.3 Market Breakdown and Data Triangulation
12.2 Data Source
12.2.1 Secondary Sources
12.2.2 Primary Sources
12.3 Author List
12.4 Disclaimer
List of TablesTable 1. Global Immune Checkpoint Agents Sales (K Units) Growth Rate Comparison by Type (2021-2027)
Table 2. Global Immune Checkpoint Agents Sales (K Units) Comparison by Application (2021-2027)
Table 3. Global Immune Checkpoint Agents Market Size by Region (US$ Million) (2016 VS 2021 VS 2027)
Table 4. Key Manufacturers Immune Checkpoint Agents Covered in This Study
Table 5. Global Immune Checkpoint Agents Sales (K Units) of Key Manufacturers (2016-2021)
Table 6. Global Immune Checkpoint Agents Sales Share by Manufacturers (2016-2021)
Table 7. Global Immune Checkpoint Agents Revenue (US$ Million) by Manufacturers (2016-2021)
Table 8. Global Immune Checkpoint Agents Revenue Share by Manufacturers (2016-2021)
Table 9. Global Market Immune Checkpoint Agents Average Price (USD/Unit) of Key Manufacturers (2016-2021)
Table 10. Manufacturers Immune Checkpoint Agents Manufacturing Sites and Area Served
Table 11. Manufacturers Immune Checkpoint Agents Product Type
Table 12. Global Immune Checkpoint Agents Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 13. Global Immune Checkpoint Agents by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Immune Checkpoint Agents as of 2020)
Table 14. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 15. Global Immune Checkpoint Agents Sales by Region (2016-2021) & (K Units)
Table 16. Global Immune Checkpoint Agents Sales Market Share by Region (2016-2021)
Table 17. Global Immune Checkpoint Agents Revenue by Region (2016-2021) & (US$ Million)
Table 18. North America Immune Checkpoint Agents Sales by Country (2016-2021) & (K Units)
Table 19. North America Immune Checkpoint Agents Sales Market Share by Country (2016-2021)
Table 20. North America Immune Checkpoint Agents Revenue by Country (2016-2021) & (US$ Million)
Table 21. North America Immune Checkpoint Agents Revenue Market Share by Country (2016-2021)
Table 22. Europe Immune Checkpoint Agents Sales by Country (2016-2021) & (K Units)
Table 23. Europe Immune Checkpoint Agents Sales Market Share by Country (2016-2021)
Table 24. Europe Immune Checkpoint Agents Revenue by Country (2016-2021) & (US$ Million)
Table 25. Europe Immune Checkpoint Agents Revenue Market Share by Country (2016-2021)
Table 26. Asia Pacific Immune Checkpoint Agents Sales by Region (2016-2021) & (K Units)
Table 27. Asia Pacific Immune Checkpoint Agents Sales Market Share by Region (2016-2021)
Table 28. Asia Pacific Immune Checkpoint Agents Revenue by Region (2016-2021) & (US$ Million)
Table 29. Asia Pacific Immune Checkpoint Agents Revenue Market Share by Region (2016-2021)
Table 30. Latin America Immune Checkpoint Agents Sales by Country (2016-2021) & (K Units)
Table 31. Latin America Immune Checkpoint Agents Sales Market Share by Country (2016-2021)
Table 32. Latin America Immune Checkpoint Agents Revenue by Country (2016-2021) & (US$ Million)
Table 33. Latin America Immune Checkpoint Agents Revenue Market Share by Country (2016-2021)
Table 34. Middle East and Africa Immune Checkpoint Agents Sales by Country (2016-2021) & (K Units)
Table 35. Middle East and Africa Immune Checkpoint Agents Sales Market Share by Country (2016-2021)
Table 36. Middle East and Africa Immune Checkpoint Agents Revenue by Country (2016-2021) & (US$ Million)
Table 37. Middle East and Africa Immune Checkpoint Agents Revenue Market Share by Country (2016-2021)
Table 38. Global Immune Checkpoint Agents Sales (K Units) by Type (2016-2021)
Table 39. Global Immune Checkpoint Agents Sales Market Share by Type (2016-2021)
Table 40. Global Immune Checkpoint Agents Revenue (Million US$) by Type (2016-2021)
Table 41. Global Immune Checkpoint Agents Revenue Share by Type (2016-2021)
Table 42. Global Immune Checkpoint Agents Price (USD/Unit) by Type (2016-2021)
Table 43. Global Immune Checkpoint Agents Sales (K Units) by Application (2016-2021)
Table 44. Global Immune Checkpoint Agents Sales Market Share by Application (2016-2021)
Table 45. Global Immune Checkpoint Agents Revenue (Million US$) by Application (2016-2021)
Table 46. Global Immune Checkpoint Agents Revenue Share by Application (2016-2021)
Table 47. Global Immune Checkpoint Agents Price (USD/Unit) by Application (2016-2021)
Table 48. Bristol Myers Squibb Corporation Information
Table 49. Bristol Myers Squibb Description and Business Overview
Table 50. Bristol Myers Squibb Immune Checkpoint Agents Sales (K Units), Revenue (Million US$), Price (USD/Unit) and Gross Margin (2016-2021)
Table 51. Bristol Myers Squibb Immune Checkpoint Agents Product
Table 52. Bristol Myers Squibb Recent Developments/Updates
Table 53. Merck Corporation Information
Table 54. Merck Description and Business Overview
Table 55. Merck Immune Checkpoint Agents Sales (K Units), Revenue (Million US$), Price (USD/Unit) and Gross Margin (2016-2021)
Table 56. Merck Immune Checkpoint Agents Product
Table 57. Merck Recent Developments/Updates
Table 58. AstraZeneca Corporation Information
Table 59. AstraZeneca Description and Business Overview
Table 60. AstraZeneca Immune Checkpoint Agents Sales (K Units), Revenue (Million US$), Price (USD/Unit) and Gross Margin (2016-2021)
Table 61. AstraZeneca Immune Checkpoint Agents Product
Table 62. AstraZeneca Recent Developments/Updates
Table 63. Roche Corporation Information
Table 64. Roche Description and Business Overview
Table 65. Roche Immune Checkpoint Agents Sales (K Units), Revenue (Million US$), Price (USD/Unit) and Gross Margin (2016-2021)
Table 66. Roche Immune Checkpoint Agents Product
Table 67. Roche Recent Developments/Updates
Table 68. Production Base and Market Concentration Rate of Raw Material
Table 69. Key Suppliers of Raw Materials
Table 70. Immune Checkpoint Agents Distributors List
Table 71. Immune Checkpoint Agents Customers List
Table 72. Immune Checkpoint Agents Market Trends
Table 73. Immune Checkpoint Agents Growth Drivers
Table 74. Immune Checkpoint Agents Market Restraints
Table 75. Global Immune Checkpoint Agents Sales Forecast by Type (2022-2027) & (K Units)
Table 76. Global Immune Checkpoint Agents Sales Market Share Forecast by Type (2022-2027)
Table 77. Global Immune Checkpoint Agents Revenue Forecast by Type (2022-2027) & (US$ Million)
Table 78. Global Immune Checkpoint Agents Revenue Market Share Forecast by Type (2022-2027)
Table 79. Global Immune Checkpoint Agents Sales Forecast by Application (2022-2027) & (K Units)
Table 80. Global Immune Checkpoint Agents Sales Market Share Forecast by Application (2022-2027)
Table 81. Global Immune Checkpoint Agents Revenue Forecast by Application (2022-2027) & (US$ Million)
Table 82. Global Immune Checkpoint Agents Revenue Market Share Forecast by Application (2022-2027)
Table 83. Global Immune Checkpoint Agents Sales Forecast by Region (2022-2027) & (K Units)
Table 84. Global Immune Checkpoint Agents Sales Market Share Forecast by Region (2022-2027)
Table 85. Global Immune Checkpoint Agents Revenue Forecast by Region (2022-2027) & (US$ Million)
Table 86. Global Immune Checkpoint Agents Revenue Market Share Forecast by Region (2022-2027)
Table 87. Research Programs/Design for This Report
Table 88. Key Data Information from Secondary Sources
Table 89. Key Data Information from Primary Sources
List of FiguresFigure 1. Product Picture of Immune Checkpoint Agents
Figure 2. Global Immune Checkpoint Agents Market Share by Type in 2020 & 2027
Figure 3. Anti-PD-L1 Drug Product Picture
Figure 4. Anti-PD-1 Drug Product Picture
Figure 5. CTLA4 Product Picture
Figure 6. Global Immune Checkpoint Agents Market Share by Application in 2020 & 2027
Figure 7. Lung Cancer
Figure 8. Colorectal Cancer
Figure 9. BreastCancer
Figure 10. Prostate Cancer
Figure 11. Melanoma
Figure 12. Blood Cancers
Figure 13. Global Immune Checkpoint Agents Revenue, (US$ Million), 2016 VS 2021 VS 2027
Figure 14. Global Immune Checkpoint Agents Market Size 2016-2027 (US$ Million)
Figure 15. Global Immune Checkpoint Agents Sales 2016-2027 (K Units)
Figure 16. Global Immune Checkpoint Agents Market Size Market Share by Region: 2016 VS 20210 VS 2027
Figure 17. Immune Checkpoint Agents Sales Share by Manufacturers in 2020
Figure 18. Global Immune Checkpoint Agents Revenue Share by Manufacturers in 2020
Figure 19. The Global 5 and 10 Largest Immune Checkpoint Agents Players: Market Share by Revenue in 2020
Figure 20. Immune Checkpoint Agents Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2016 VS 2021
Figure 21. Global Immune Checkpoint Agents Sales Market Share by Region (2016-2021)
Figure 22. Global Immune Checkpoint Agents Sales Market Share by Region in 2020
Figure 23. Global Immune Checkpoint Agents Revenue Market Share by Region (2016-2021)
Figure 24. Global Immune Checkpoint Agents Revenue Market Share by Region in 2020
Figure 25. U.S. Immune Checkpoint Agents Revenue Growth Rate (2016-2021) (US$ Million)
Figure 26. Canada Immune Checkpoint Agents Revenue Growth Rate (2016-2021) (US$ Million)
Figure 27. Germany Immune Checkpoint Agents Revenue Growth Rate (2016-2021) (US$ Million)
Figure 28. France Immune Checkpoint Agents Revenue Growth Rate (2016-2021) (US$ Million)
Figure 29. U.K. Immune Checkpoint Agents Revenue Growth Rate (2016-2021) (US$ Million)
Figure 30. Italy Immune Checkpoint Agents Revenue Growth Rate (2016-2021) (US$ Million)
Figure 31. Russia Immune Checkpoint Agents Revenue Growth Rate (2016-2021) (US$ Million)
Figure 32. China Immune Checkpoint Agents Revenue Growth Rate (2016-2021) (US$ Million)
Figure 33. Japan Immune Checkpoint Agents Revenue Growth Rate (2016-2021) (US$ Million)
Figure 34. South Korea Immune Checkpoint Agents Revenue Growth Rate (2016-2021) (US$ Million)
Figure 35. India Immune Checkpoint Agents Revenue Growth Rate (2016-2021) (US$ Million)
Figure 36. Australia Immune Checkpoint Agents Revenue Growth Rate (2016-2021) (US$ Million)
Figure 37. Taiwan Immune Checkpoint Agents Revenue Growth Rate (2016-2021) (US$ Million)
Figure 38. Indonesia Immune Checkpoint Agents Revenue Growth Rate (2016-2021) (US$ Million)
Figure 39. Thailand Immune Checkpoint Agents Revenue Growth Rate (2016-2021) (US$ Million)
Figure 40. Malaysia Immune Checkpoint Agents Revenue Growth Rate (2016-2021) (US$ Million)
Figure 41. Philippines Immune Checkpoint Agents Revenue Growth Rate (2016-2021) (US$ Million)
Figure 42. Vietnam Immune Checkpoint Agents Revenue Growth Rate (2016-2021) (US$ Million)
Figure 43. Mexico Immune Checkpoint Agents Revenue Growth Rate (2016-2021) (US$ Million)
Figure 44. Brazil Immune Checkpoint Agents Revenue Growth Rate (2016-2021) (US$ Million)
Figure 45. Argentina Immune Checkpoint Agents Revenue Growth Rate (2016-2021) (US$ Million)
Figure 46. Turkey Immune Checkpoint Agents Revenue Growth Rate (2016-2021) (US$ Million)
Figure 47. Saudi Arabia Immune Checkpoint Agents Revenue Growth Rate (2016-2021) (US$ Million)
Figure 48. U.A.E Immune Checkpoint Agents Revenue Growth Rate (2016-2021) (US$ Million)
Figure 49. Sales Market Share of Immune Checkpoint Agents by Type (2016-2021)
Figure 50. Sales Market Share of Immune Checkpoint Agents by Application (2016-2021)
Figure 51. Sales Market Share of Immune Checkpoint Agents by Application in 2020
Figure 52. Revenue Share of Immune Checkpoint Agents by Application (2016-2021)
Figure 53. Revenue Share of Immune Checkpoint Agents by Application in 2020
Figure 54. Manufacturing Cost Structure of Immune Checkpoint Agents
Figure 55. Manufacturing Process Analysis of Immune Checkpoint Agents
Figure 56. Immune Checkpoint Agents Industrial Chain Analysis
Figure 57. Channels of Distribution
Figure 58. Distributors Profiles
Figure 59. Bottom-up and Top-down Approaches for This Report
Figure 60. Data Triangulation
Figure 61. Key Executives Interviewed